Home › Calculator › JNJ Dividend Calculator 2026
JNJ Dividend DRIP Calculator 2026
2.04% YieldHealthcareJohnson & Johnson · NYSE
Price: $258.45 · Annual div: $5.28/share · Frequency: quarterly · Payout ratio: 48% · Ex-div: 2026-08-25
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When JNJ pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your JNJ snowball 📈
$10,000 in JNJ → $19.1K in 10 years · $33.41/month
About Johnson & Johnson (JNJ) — Dividend Analysis 2026
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Compare JNJ with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full JNJ DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open JNJ position with:
🌍 JNJ Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold JNJ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.04% | -0.76% | $204 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.73% | -1.07% | $173 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.63% | -1.17% | $163 / yr |
| 🇬🇧 UK ISA | 0% | 2.04% | -0.76% | $204 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.86% | -0.94% | $186 / yr |
| 🇨🇦 TFSA | 0% | 2.04% | -0.76% | $204 / yr |
| 🇨🇦 CA Taxable | 25% | 1.53% | -1.27% | $153 / yr |
| 🇦🇺 Super (pension) | 15% | 1.73% | -1.07% | $173 / yr |
| 🇦🇺 AU Taxable | 30% | 1.43% | -1.37% | $143 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.50% | -1.30% | $150 / yr |
| 🇫🇷 FR Taxable | 30% | 1.43% | -1.37% | $143 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 JNJ Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $5.28/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 JNJ Dividend Payment Schedule
JNJ pays quarterly — 4 times per year. Ex-div: 2026-08-25.
📊 JNJ vs Healthcare Benchmarks
How JNJ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for JNJ sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ JNJ Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-09-08 | 113.098 | — | — | ||
| A-Award | 2026-09-08 | 135.717 | — | — | ||
| A-Award | 2026-09-08 | 180.956 | — | — | ||
| M-Exempt | 2026-09-02 | 22,527 | $151.41 | $3.41M | ||
| M-Exempt | 2026-09-02 | 11,070 | $131.94 | $1.46M | ||
| Sale | 2026-09-02 | 22,527 | $274.74 | $6.19M | ||
| M-Exempt | 2026-09-02 | 11,070 | $131.94 | $1.46M | ||
| M-Exempt | 2026-09-02 | 22,527 | $151.41 | $3.41M | ||
| Other | 2026-09-01 | 15,839 | $243.45 | $3.86M | ||
| Other | 2026-09-01 | 25,493 | $156.15 | $3.98M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare JNJ with peers: JNJ vs ABBV · JNJ vs AMGN · JNJ vs AZN
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where JNJ earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the JNJ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Johnson & Johnson (JNJ) is currently trading at $258.45, 8% below its 52-week high. The current dividend yield is 2.04% based on an annual payout of $5.28 per share.
Johnson & Johnson Offers Strong Dividend Safety and Steady Growth
AI SummaryJohnson & Johnson stands as a premier dividend investment within the healthcare sector, boasting a robust market capitalization of $626.6 billion. It currently offers an annual dividend of $5.28, translating to a moderate yield of 2.03% at a share price of $260.01. The dividend is exceptionally secure, backed by a conservative payout ratio of 48% and a manageable P/E ratio of 23.6. The company demonstrates a reliable growth trajectory, supported by a 5-year dividend CAGR of 5.1%. This sustainable payout reflects disciplined financial management and steady cash generation, making JNJ a dependable option for income-focused portfolios prioritizing long-term stability over high initial yield.
- Ongoing litigation related to talc and pharmaceutical products
- Patent expirations on key pharmaceutical drugs impacting revenue growth
Generated by AI using live market data. For educational purposes only — not financial advice.
Latest JNJ News
LiveHow investors use the JNJ dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.